Warren Eric — SEC Form 4 filings
SEC reporting owner CIK 1916048. 16 Form 4 filings on record with FilingPulse; latest filed 2026-08-25.
Transaction summary — filings shown
Covers all 16 filings on record, filed 2024-03-15 to 2026-08-25. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 14 legs across 14 filings — 129,976 shares, $3,112,717 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
- Largest priced transaction: sale of 104,124 shares @ $25.90 ($2,696,322) in Mineralys Therapeutics, Inc., filed 2026-06-30.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | Chief Commercial Officer | 3 | — | 3 legs · 118,999 sh · $3,089,396 | 6 |
| Esperion Therapeutics, Inc. (ESPR) | Chief Commercial Officer | 13 | — | 11 legs · 10,977 sh · $23,321 | 4 |
Form 4 filings — Warren Eric
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-25 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Option exercise (M): 7,437 @ $13.24 · Sale (S): 7,437 @ $25.98 · Option exercise (M): 7,437 (derivative) @ $0 | EDGAR |
| 2026-07-23 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Option exercise (M): 7,438 @ $13.24 · Sale (S): 7,438 @ $26.87 · Option exercise (M): 7,438 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Option exercise (M): 104,124 @ $13.24 · Sale (S): 104,124 @ $25.90 · Option exercise (M): 104,124 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 108 @ $0.98 | EDGAR |
| 2025-03-19 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 2,433 @ $1.49 | EDGAR |
| 2025-03-17 | 4 | Esperion Therapeutics, Inc. (ESPR) | Grant/award (A): 213,000 @ $0 · Grant/award (A): 191,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 239 @ $1.87 | EDGAR |
| 2024-12-18 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 2,234 @ $2.43 | EDGAR |
| 2024-11-20 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 197 @ $2.17 | EDGAR |
| 2024-10-18 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 107 @ $2.12 | EDGAR |
| 2024-09-18 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 2,608 @ $1.78 | EDGAR |
| 2024-08-20 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 211 @ $1.95 | EDGAR |
| 2024-07-19 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 108 @ $2.59 | EDGAR |
| 2024-06-20 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 2,540 @ $2.86 | EDGAR |
| 2024-05-20 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 192 @ $2.48 | EDGAR |
| 2024-03-15 | 4 | Esperion Therapeutics, Inc. (ESPR) | Grant/award (A): 100,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1916048 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →